OccuLogix Conducting Rheo Clinical Trial, Crossover Studies Simultaneously
This article was originally published in The Gray Sheet
Executive Summary
FDA approval of two open-label, multi-center crossover studies of OccuLogix' Rheo therapy for "dry" age-related macular degeneration (AMD) will provide a first look of the device's long-term efficacy